Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy

References

• International Diabetes Federation. Diabetes Backgrounder. Available at: http://www.eatlas.idf.org/webdata/docs/background_opening_pc.pdf [accessed 2 September 2011].
   Google Scholar
• Centers for Disease Control and Prevention. Centers for Disease Control detailed data for diagnosed diabetes. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/tnumage.htm [accessed 15 September 2011].
   Google Scholar
• Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, . Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35 Suppl 1:S11–63.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. Global guideline for type 2 diabetes. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. [accessed 2 September 2011].
   Google Scholar
• Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, . American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13 Suppl 1:1–68.
   PubMedGoogle Scholar
• Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81–6.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, . Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17–30.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–12.
   PubMed Web of Science ®Google Scholar
• Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am. 2005;34:77–98.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes. 2005;23:78–86.
   Google Scholar
• Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, . Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753–60.
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, . Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361: 1736–47.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, . Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32: 193–203.
   PubMed Web of Science ®Google Scholar
• DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254–64.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–6.
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, . Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–5.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, . Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 Study). Diabetes Obes Metab. 2006;8:58–66.
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, . A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33:1176–8.
   PubMed Web of Science ®Google Scholar
• Sasali A, Leahy JL. Insulin therapy for type 2 diabetes. Curr Diabetes Rep. 2003;3:378–85.
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, . Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–72.
   PubMed Web of Science ®Google Scholar
• Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough—what next? Diabetes Metab Res Rev. 2007;23:257–64.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008; 31:20–5.
   PubMed Web of Science ®Google Scholar
• Fritsche A, Larbig M, Owens D, Haring H-U. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes—results of the GINGER study. Diabetes Obes Metab. 2010;12:115–23.
   PubMed Web of Science ®Google Scholar
• Davies M, Sinnassamy P, Storms F, Gomis R. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. Diabetes Res Clin Pract. 2008;79:368–75.
   PubMed Web of Science ®Google Scholar
• Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med. 2008;121:S9–19.
   PubMed Web of Science ®Google Scholar
• Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008;6:54–67.
   PubMedGoogle Scholar
• Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, . Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med. 1997;157:1249–55.
   PubMed Web of Science ®Google Scholar
• Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther. 1997;19:62–72.
   Google Scholar
• Heller S, Bode BW, Kozlovski P, Svendsen AL. Examining the glycemic and hypoglycemic benefits with rapid-acting insulin analogs: a meta-analysis of insulin aspart vs regular insulin in randomized controlled trials [abstract 505-P]. Presented at: American Diabetes Association 69th Scientific Sessions, 5–9 June 2009, New Orleans, LA, USA.
   Google Scholar
• Owens DR, Schalkwyk C, Smith P, Beer S, Goenka N, Bain SC, . Algorithm for the introduction of rapid-acting insulin analogues in patients with type 2 diabetes on basal insulin therapy. Pract Diab Int. 2009;26:70–7.
   Google Scholar
• Pearson J, Powers MA. Systematically initiating insulin: the staged diabetes management approach. Diabetes Educ. 2006;32:19S–28S.
   Google Scholar
• Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab. 2008;10:1178–85.
   PubMed Web of Science ®Google Scholar
• Ampudia-Blasco FJ, Rossetti P, Ascaso JF. Basal plus basal-bolus approach in type 2 diabetes. Diabetes Technol Ther. 2011;13 Suppl 1:S75–83.
   Google Scholar
• Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, . Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31:1305–10.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, . Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442–51.
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554–9.
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab. 2006;32:7–13.
   PubMed Web of Science ®Google Scholar
• Blonde L, Merilainen M, Karwe V, Raskin P. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE study. Diabetes Obes Metab. 2009;11:623–31.
   PubMed Web of Science ®Google Scholar
• Meneghini L, Mersebach H, Kumar S, Svendsen AL, Hermansen K. A comparison of two intensification regimens with rapid-acting insulin aspart in type 2 diabetes inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the STEP-Wise randomized study. Endocr Pract. 2011;17:727–36.
   PubMed Web of Science ®Google Scholar
• Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med. 2004;71:385–6, 391–2.
   PubMed Web of Science ®Google Scholar
• Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70:489–500.
   PubMed Web of Science ®Google Scholar
• Davis NJ, Wylie-Rosett J. Death to carbohydrate counting? Diabetes Care. 2008;31:1467–8.
   Google Scholar
• National Institute for Health and Clinical Excellence. The management of type 2 diabetes. Available at: http://www.nice.org.uk/nicemedia/live/12165/44322/44322.pdf [accessed 10 January 2010].
   Google Scholar
• Akram K, Pedersen-Bjergaard U, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. J Diabetes Complications. 2006;20:402–8.
   PubMed Web of Science ®Google Scholar
• Colberg S. The impact of exercise on insulin action in type 2 diabetes mellitus: relationship to prevention and control. Insulin. 2006;1:85–98.
   Google Scholar
• Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C, White RD. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care. 2006;29:1433–8.
   PubMed Web of Science ®Google Scholar
• Plockinger U, Topuz M, Riese B, Reuter T. Risk of exercise-induced hypoglycaemia in patients with type 2 diabetes on intensive insulin therapy: comparison of insulin glargine with NPH insulin as basal insulin supplement. Diabetes Res Clin Pract. 2008;81:290–5.
   PubMedGoogle Scholar
• Pearson T. Exercise, insulin, and type 2 diabetes. Medscape Diabetes Endocrinol. 2008. Available at: http://www.medscape.com/viewarticle/572219 [accessed 26 June 2012].
   Google Scholar
• Lowe J, Linjawi S, Mensch M, James K, Attia J. Flexible eating and flexible insulin dosing in patients with diabetes: results of an intensive self-management course. Diabetes Res Clin Pract. 2008;80:439–43.
   Google Scholar
• Braun A, Samann A, Kubiak T, Zieschang T, Kloos C, Muller UA, . Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus. Patient Educ Couns. 2008;73:50–9.
   PubMed Web of Science ®Google Scholar
• Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337–442.
   PubMed Web of Science ®Google Scholar
• Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–7.
   Google Scholar